All Stories

  1. Exploring the outer limits of polyplexes
  2. Delivery of Chemotherapy Agents and Nucleic Acids with pH-Dependent Nanoparticles
  3. pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges
  4. Marked increase in tumor transfection with a truncated branched polymer
  5. Location of a single histidine within peptide carriers increases mRNA delivery
  6. The Multifaceted Histidine-Based Carriers for Nucleic Acid Delivery: Advances and Challenges
  7. Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin
  8. Targeting Cancer with Peptide RNAi Nanoplexes
  9. Advances in Delivery Systems for Doxorubicin
  10. Simultaneous silencing of TGF-β1 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis
  11. Targeted Delivery of siRNA Therapeutics to Malignant Tumors
  12. NRP1 transport of cancer therapeutics mediated by tumor-penetrating peptides
  13. Targeing Invasive Fungi with the Silver-Bullet Peptide
  14. NRP-1 mediated transport of H2K polyplexes to tumors
  15. siRNA nanoparticles: the future of RNAi therapeutics for oncology?
  16. Increased tumor distribution and expression of histidine-rich plasmid polyplexes
  17. Direct Observation of Dynamic Mechanical Regulation of DNA Condensation by Environmental Stimuli
  18. Enhancement of antifungal activity by integrin-targeting of branched histidine rich peptides
  19. Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds
  20. Surface-Modified HK:siRNA Nanoplexes with Enhanced Pharmacokinetics and Tumor Growth Inhibition
  21. Buffering Capacity and Size of siRNA Polyplexes Influence Cytokine Levels
  22. Zinc finger nucleases: Tailor-made for gene therapy
  23. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo
  24. Vaccines targeting the neovasculature of tumors
  25. Peptide-based antifungal therapies against emerging infections
  26. Leveraging therapeutic potential of multi-targeted siRNA inhibitors
  27. Advances in systemic siRNA delivery
  28. Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth
  29. Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts
  30. Histidine-lysine peptides as carriers of nucleic acids
  31. Synthetic Histidine-Rich Peptides Inhibit Candida Species and Other Fungi In Vitro: Role of Endocytosis and Treatment Implications
  32. 203. Salt Conditions during Polyplex Formation Significantly Alters Transfection
  33. A branched histidine/lysine peptide, H2K4b, in complex with plasmids encoding antitumor proteins inhibits tumor xenografts
  34. Transporting silence: Design of carriers for siRNA to angiogenic endothelium
  35. Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo
  36. Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection
  37. Alteration in the IL-2 signal peptide affects secretion of proteinsin vitro andin vivo
  38. Highly branched HK peptides are effective carriers of siRNA
  39. Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles
  40. Targeting Tumor Angiogenesis with Gene Therapy
  41. Branched co-polymers of histidine and lysine are efficient carriers of plasmids
  42. Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes
  43. Antiangiogenic Gene Therapy in Cancer
  44. In VivoGene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes
  45. Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breast Cancerin Vivo
  46. Systemic gene therapy with p53 inhibits breast cancer recent advances and therapeutic implications
  47. Parenteral Gene Therapy with p53 Inhibits Human Breast TumorsIn VivoThrough a Bystander Mechanism Without Evidence of Toxicity
  48. Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Cancer in Nude Mice
  49. ADHD AND THE THYROID CONTROVERSY
  50. Analysis of the binding of 3,3',5-triiodo-L-thyronine and its analogs to mutant human .beta.1 thyroid hormone receptors: A model of the hormone binding site
  51. Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone.
  52. Attention Deficit-Hyperactivity Disorder in People with Generalized Resistance to Thyroid Hormone
  53. Identification of a novel mutation in the gene encoding the β-triiodothyronine receptor in a patient with apparent selective pituitary resistance to thyroid hormone
  54. Thyrotropin-secreting pituitary carcinoma
  55. Thyrotropin-secreting pituitary carcinoma.
  56. The proto-oncogenes c-fos and c-jun modulate thyroid hormone inhibition of human thyrotropin β subunit gene expression in opposite directions
  57. Correlations of language abnormalities with localization of mutations in the beta-thyroid hormone receptor in 13 kindreds with generalized resistance to thyroid hormone: identification of four new mutations
  58. Correlations of language abnormalities with localization of mutations in the beta-thyroid hormone receptor in 13 kindreds with generalized resistance to thyroid hormone: identification of four new mutations.
  59. Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain.
  60. Structural analogues of pyrroline 5-carboxylate specifically inhibit its uptake into cells
  61. An Assay for Pyrroline 5-Carboxylate Based on its Interaction with Cysteine
  62. The uptake of pyrroline 5-carboxylate. Group translocation mediating the transfer of reducing-oxidizing potential.
  63. DNA Delivery to Cells in Culture Using Peptides
  64. Inhibiting Cancer Angiogenesis With Molecular Therapy